Last month, NIH and NCATS launched the Discovering New Therapeutic Uses for Existing Molecules pilot program, which will match scientists with industry molecular compounds. Since then, five new industry collaborators joined the initiative, NCATS released funding information and the number of compounds the companies are making available to researchers more than doubled to a total of 58.
Abbott, Bristol-Myers Squibb Co., GlaxoSmithKline, Janssen Pharmaceutical & Research Development LLC and Sanofi now have joined Pfizer, AstraZeneca and Eli Lilly and Co. in the innovative approach to research.
NCATS created the program to re-engineer the research pipeline. By crowdsourcing compounds that already have cleared several key steps in the development process, including safety testing in humans, scientists nationwide and NIH intramural researchers have the opportunity to contribute their expertise to advancing these resources for new disease therapies.
Each compound has advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued for business reasons. Preliminary information about the compounds is available at http://ncats.nih.gov/therapeutics-directory.html.
For more information about the program, visit http://ncats.nih.gov/therapeutics.html.